Form 8-K - Current report:
SEC Accession No. 0001479290-24-000034
Filing Date
2024-02-28
Accepted
2024-02-28 16:07:18
Documents
18
Period of Report
2024-02-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20240223.htm   iXBRL 8-K 38351
2 EX-10.1 ajinomotoamendmentno2_ex101.htm EX-10.1 42492
3 EX-10.2 ex102_rvncsjutsseparationa.htm EX-10.2 125372
4 EX-99.1 rvncq423er8-k_exhibit991.htm EX-99.1 238136
8 image.jpg GRAPHIC 3893
  Complete submission text file 0001479290-24-000034.txt   636351

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240223.xsd EX-101.SCH 1939
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240223_lab.xml EX-101.LAB 24139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240223_pre.xml EX-101.PRE 12544
20 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240223_htm.xml XML 2822
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 24695283
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)